2021/04/30 ALA-1000 was granted by Intellectual Property Office of New Zealand.Patent No. 750367.
Comments Off on 2021/04/30 ALA-1000 was granted by Intellectual Property Office of New Zealand.Patent No. 750367.
3 . 5 . 2021
2021/04/16 ALA-1000 Receive notice of allowance for patent registration from Korean Intellectual Property Office (Application No. 10-2019-7009185).
Comments Off on 2021/04/16 ALA-1000 Receive notice of allowance for patent registration from Korean Intellectual Property Office (Application No. 10-2019-7009185).
21 . 4 . 2021
2021/04/12 ALA-1000 Receive Decision of Grant from Federal Service for Intellectual Property (ROSPATENT) (Application No. 2019102895).
Comments Off on 2021/04/12 ALA-1000 Receive Decision of Grant from Federal Service for Intellectual Property (ROSPATENT) (Application No. 2019102895).
21 . 4 . 2021
2021/04/13 -Alar Pharmaceuticals Inc., participates in American Society of Addiction Medicine (ASAM) Virtual 2021, the nation’s largest and premier conference on addiction medicine, which will hold this year between 22 – 24 April.
https://www.eventscribe.net/2021/ASAM/SearchByExpoCompany.asp
Comments Off on 2021/04/13 -Alar Pharmaceuticals Inc., participates in American Society of Addiction Medicine (ASAM) Virtual 2021, the nation’s largest and premier conference on addiction medicine, which will hold this year between 22 – 24 April.
13 . 4 . 2021
2021/03/10 Breaking the Cycle of Opioid Addiction: Alar Presents Positive Interim Results of Long-acting Buprenorphine Injectable (ALA-1000) in Opioid Dependent Patients
Breaking the Cycle of Opioid Addiction: Alar Presents Positive Interim Results of Long-acting Buprenorphine Injectable (ALA-1000) in Opioid Dependent Patients ALA-1000 is the first, three-month slow-release Buprenorphine injection. Initial results show a low initial burst without dose dumping effect, good safety, and tolerability. ALA-1000 has the potential to significantly increase compliance and reduce the risk of relapse in patients treated and stabilized with oral medications or other, shorter-interval Buprenorphine LAIs.…
Comments Off on 2021/03/10 Breaking the Cycle of Opioid Addiction: Alar Presents Positive Interim Results of Long-acting Buprenorphine Injectable (ALA-1000) in Opioid Dependent Patients
10 . 3 . 2021
2020/08/03 ALA -1000 Receive notice of patent allowance from the IP Australia.
Comments Off on 2020/08/03 ALA -1000 Receive notice of patent allowance from the IP Australia.
25 . 8 . 2020